Literature DB >> 9786066

Comparison of porcine hepatocytes with human hepatoma (C3A) cells for use in a bioartificial liver support system.

L Wang1, J Sun, L Li, D Mears, M Horvat, A G Sheil.   

Abstract

Cells from primary porcine hepatocytes (PPH) and the immortalized human hepatoma cell line C3A are both used in bioartificial liver support systems (BALSS). In this work the viability and metabolic capacity of PPH and C3A cells cultured in different media were compared. Also, because the cells come into direct or indirect contact with human blood components in BALSS, the effects of human complement on survival and functions of the cells was evaluated. For short-term culture, maintenance of PPH viability was essential for retention of P450IA1 activity (r = 0.882, p < 0.01) and effective ammonia clearance (r = -0.791, p < 0.01). When cell viability was below 60% P450IA1 activity could not be recorded and nitrogen elimination activity significantly diminished. In contrast to PPH, ammonia levels were markedly increased for C3A cells in all culture media tested (p < 0.01). Ammonia increase correlated with C3A viability (r = 0.896, p < 0.05). PPH metabolic function was superior to that of the C3A cell line when evaluated by P450IA1 activity, ammonia removal, and amino acid metabolism. When PPH were incubated in human plasma (HP) or human serum (HS) there was rapid and irreversible deterioration of viability occurring within 9 h. This toxic effect could be prevented by the inactivation of complement. When sodium citrate dissolved in dextrose was added to medium, there was considerable damage to both PPH and the C3A cell line. However, there was no demonstrable toxic effect when hepatic cells of either type were exposed to heparin. We conclude that PPH cultivated in complement-inactivated HP or HS are to be preferred to C3A for clinical application of BALSS, and that heparin should be preferred for anticoagulation in BALSS.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9786066     DOI: 10.1177/096368979800700505

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.139


  7 in total

Review 1.  Cell therapies for liver diseases.

Authors:  Yue Yu; James E Fisher; Joseph B Lillegard; Brian Rodysill; Bruce Amiot; Scott L Nyberg
Journal:  Liver Transpl       Date:  2012-01       Impact factor: 5.799

2.  Feeder-independent continuous culture of the PICM-19 pig liver stem cell line.

Authors:  Neil C Talbot; Le Ann Blomberg; Wesley M Garrett; Thomas J Caperna
Journal:  In Vitro Cell Dev Biol Anim       Date:  2010-07-07       Impact factor: 2.416

3.  Evaluation and optimization of hepatocyte culture media factors by design of experiments (DoE) methodology.

Authors:  Jia Dong; Carl-Fredrik Mandenius; Marc Lübberstedt; Thomas Urbaniak; Andreas K N Nüssler; Daniel Knobeloch; Jörg C Gerlach; Katrin Zeilinger
Journal:  Cytotechnology       Date:  2008-10-07       Impact factor: 2.058

4.  A bioartificial liver device based on three-dimensional culture of genetically engineered hepatoma cells using hollow fibers.

Authors:  Yusuke Fujii; Kengo Higashi; Hiroshi Mizumoto; Masamichi Kamihira; Toshihisa Kajiwara
Journal:  Cytotechnology       Date:  2020-02-04       Impact factor: 2.058

Review 5.  Is there a future for liver-assist devices?

Authors:  P Rosenthal
Journal:  Curr Gastroenterol Rep       Date:  2000-02

6.  Optimization of mass transfer for toxin removal and immunoprotection of hepatocytes in a bioartificial liver.

Authors:  Geir I Nedredal; Bruce P Amiot; Peter Nyberg; Jennifer Luebke-Wheeler; Joseph B Lillegard; Travis J McKenzie; Scott L Nyberg
Journal:  Biotechnol Bioeng       Date:  2009-12-01       Impact factor: 4.530

7.  Profiling the impact of medium formulation on morphology and functionality of primary hepatocytes in vitro.

Authors:  Leonard J Nelson; Philipp Treskes; A Forbes Howie; Simon W Walker; Peter C Hayes; John N Plevris
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.